SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on October 24, 2002; DOI 10.1182/blood-2002-03-0973. This Article Full Text (PDF) All Versions of this Article: 2002-03-0973v1 101/6/2314    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Vuckovic, S. Articles by Hart, D. N J Search for Related Content PubMed PubMed Citation Articles by Vuckovic, S. Articles by Hart, D. N J Social Bookmarking                   What's this? Submitted March 28, 2002 Accepted October 20, 2002 Granulocyte-colony stimulating factor increases blood CD123hi dendritic cells with altered CD62L and CCR7 expression Slavica Vuckovic, Min Kim, Daila Khalil, Cameron J Turtle, Georgina V Crosbie, Noel Williams, Len Brown, Katrina Williams, Cathryn Kelly, Penny Stravos, Robyn Rodwell, Geoff R Hill, Susan Wright, Kerry A Taylor, Devinder Gill, Paula Marlton, Ken Bradstock, and Derek N J Hart* Mater Medical Research Institute, South Brisbane, QLD, Australia Haematology/Oncology, Mater Misericordiae Hospital, South Brisbane, QLD, Australia Westmead Hospital, Blood & Bone Marrow Transplant Service, Westmead, NSW, Australia Princess Alexandra Hospital, Wooolloongabba, QLD, Australia * Corresponding author; email: dhart{at}mmri.mater.org.au. Changes in blood dendritic cell (BDC) counts (CD123hiBDC and CD11c+BDC) and expression of CD62L, CCR7 and CD49d were analysed in healthy donors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) patients, who received granulocyte-colony stimulating factor (G-CSF)-containing peripheral blood stem cell (PBSC) mobilization protocols. Low dose G-CSF in healthy donors (8-10µg/kg/day s.c.) and high dose G-CSF in patients (30µg/kg/day) increased CD123hiBDC (2-22 fold, means 3.7x106/L-17.7x106/L and 1.9x106/L-12.0x106/L) in healthy donors and MM but decreased CD11c+BDC (2-10 fold, means 57x106/L-1.6x106/L) in NHL patients, on the day of apheresis, compared to steady state. After apheresis, CD123hiBDC counts remained high, whereas low CD11c+BDC counts tended to recover in the following 2-5 days. Downregulation of CD62L and upregulation of CCR7 on CD123hiBDC were found in a majority of healthy donors and MM patients. CD49d expression was unchanged. Thus, PBSC mobilization may change BDC counts by altering molecules necessary for BDC homing from blood into tissues. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. L. Salem, C. M. Diaz-Montero, A. A. Al-Khami, S. A. El-Naggar, O. Naga, A. J. Montero, A. Khafagy, and D. J. Cole Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C) J. Immunol., February 15, 2009; 182(4): 2030 - 2040. [Abstract] [Full Text] [PDF] E. S. Morris, K. P. A. MacDonald, and G. R. Hill Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood, May 1, 2006; 107(9): 3430 - 3435. [Abstract] [Full Text] [PDF] S. Rutella, F. Zavala, S. Danese, H. Kared, and G. Leone Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance J. Immunol., December 1, 2005; 175(11): 7085 - 7091. [Abstract] [Full Text] [PDF] F. F. Fagnoni, B. Oliviero, G. Giorgiani, P. De Stefano, A. Deho, C. Zibera, N. Gibelli, R. Maccario, G. Da Prada, M. Zecca, et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation Blood, July 1, 2004; 104(1): 281 - 289. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020